Dr. Marc Hedrick is the President and CEO at Plus Therapeutics, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.
Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
Andrew Sims is Vice President and Chief Financial Officer at Plus Therapeutics, Inc. Mr. Sims arrived at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over 50 acquisitions ranging from $5 million to $4 billion in purchase price.
Mr. Sims is a native of the United Kingdom and is now a proud U.S. citizen. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. He is a graduate of Buckingham University in the United Kingdom.
Greg Fuller, MD, PhD is the Vice President of Medical Affairs and Medical Director at Plus Therapeutics.
Before joining Plus, Dr. Fuller served as Professor and Chief Neuropathologist at The University of Texas M D Anderson Cancer Center in the Department of Pathology, with a joint appointment in the Department of Neuroradiology, where he was a faculty member from 1992 – 2023. He is certified by the American Board of Pathology in Anatomic Pathology and Neuropathology. Dr. Fuller has published over 400 papers in peer-reviewed scientific journals, over 60 book chapters, and two books. He was President of the United States and Canadian Academy of Pathology from 2011-2012.
Dr. Fuller’s advocacy of the highest standards of excellence in Diagnostic Medicine, with investigative, patient care, and didactic skills honed over 47 years of rigorous training and academic service, has influenced successive waves of young physicians and scientists.
A three-decade tenure at MDACC enabled Dr. Fuller to exercise an educational reach of global dimensions, in terms of breadth, as illustrated by invited lectures at vanguard institutions worldwide, as well as in terms of depth, ranging from such apogee honors as being a Keynote Plenary Speaker at the historic 100th Anniversary Congress of the International Academy of Pathology, held in Montreal in 2006, down to the seemingly quotidian, but not in the least less important, presentation of multiple talks to Title I (low-income high-poverty) elementary and high school students in rural east Tennessee.
Dr. Fuller received his MD from Baylor College of Medicine, followed by his Residency in Anatomic Pathology and Fellowship in Neuropathology at Duke University. He earned his PhD from MD Anderson Cancer Center/UTHealth Graduate School of Biomedical Sciences, and his BS in Zoology from Texas A&M University (where he was inducted into the College of Science Academy of Distinguished Former Students).
Russ Havranek is the Vice President of Corporate Strategy and New Product Planning at Plus Therapeutics, Inc. He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics.
Mr. Havranek has over 26 years of leadership experience developing and commercializing diagnostic and therapeutic products at global, publicly traded, biopharma and medical device companies. His prior roles in marketing, strategy, business development, general management, and R&D focused on the oncology, rare disease, cardiology, and orthopedic markets. These roles were held at Johnson & Johnson, Guidant (now Abbott), Genentech (now Roche), DJO Global (now Enovis), Volcano (now Philips), and CareFusion (now Becton Dickinson).
Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.
Melissa Moore, PhD is the Vice President of Clinical Research at Plus Therapeutics, Inc.
Dr. Moore has over fifteen years of experience in oncology, molecular diagnostics and radiotherapeutic drug development. Her corporate roles include start-up leadership experience, full lifecycle product development, funding & capitalization, manufacturing and regulatory strategy. Prior to joining Plus Therapeutics, she was a co-founder of SOFIE and served as its Chief Technology Officer. While at Sofie, she was specifically responsible for leading the Clinical Development Program, Radiopharmaceutical Contract Manufacturing Operations, and the Quality Assurance/Regulatory Affairs Division. Dr. Moore has also led Development at the Damon Runyon Cancer Research Foundation in New York.
Previously, she was a Visiting Scientist at University of California, Los Angeles and principal investigator on numerous governmental grants and contracts. Additionally, she sits on various related scientific review boards for the National Institute of Health. Dr. Moore received her Bachelor of Science degree from University of California, Berkeley and her PhD from University of California, Los Angeles, where she also completed her post-doctorate research in Molecular and Medical Pharmacology.
Dr. Barbara Blouw has a Ph.D. from Utrecht University in the Netherlands and completed her postdoctoral research at the Sanford Burnham Prebys, Medical Discovery Institute, and the University of California, San Diego Division of Biological Sciences in basic cancer biopsy. Professionally, she has worked for Navigate Biopharma (a Novartis Company), Halozyme and Biocept. Dr. Blouw has a broad background in oncology research, clinical trial design, regulatory submissions, biostatistics, and clinical operations. She also has expertise in CNS biomarker development using in vitro and in vivo preclinical models and assay development and validations for clinical trial testing per the College of American Pathologists Laboratory Accreditation Program and Clinical Laboratory Improvement Amendments.
